局所的に進行したまたは転移した肉腫を治療した患者におけるシンチリマブとアノチニブの併用:前向きな単一アームの第2相臨床試験
Heng Fu1, Zengjun Liu2, Mengyao Liu2
1Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji Nan, China.
Cancer immunology research
|August 28, 2025
まとめ
シンティリマブとアンロチニブは,進行した肉腫の治療に有望であり,客観的な応答率30. 9%を達成しました. 三次リンパ性構造はよりよい反応を予測し,サルコマ患者の個別化治療戦略を示唆する.
科学分野:
- 医療腫瘍学
- 免疫療法
- サルコマ 研究
背景:
- 先進的な肉腫は標準治療後の治療選択肢が限られている.
- 新しい組み合わせの治療法の調査は 患者の治療結果を改善するために不可欠です
研究 の 目的:
- 進行したサルコマの患者でシンチリマブとアノチニブを併用した有効性と安全性を評価する.
- 治療反応における三次リンパ性構造 (TLS) の予測的役割を調査する.
主な方法:
- 18歳から75歳までの,先行した肉腫の患者で,先行した全身療法による臨床試験です.
- 患者は3週間ごとにシンチリマブ (200 mg) とアノチチニブ (8, 10, 12 mg) を投与された.
- 客観的な応答率 (ORR),無進行生存率 (PFS),全生存率 (OS),および有害事象 (AEs) を評価した.
主要な成果:
- ORRは30. 9%,疾病制御率 (DCR) は76. 2%でした.
- PFSの中央値は5. 0ヶ月で,OSの中央値は達成されなかった.
- TLS陽性患者 (71. 4%) と,TLS陰性患者 (25. 0%) と比較して,より高いORRが観察されました.
結論:
- シンチリマブとアンロチニブは,進行した肉腫において,有意な抗腫瘍活性と管理可能な毒性を示しています.
- TLSの状態は,この組み合わせ治療に対する反応を予測する潜在的なバイオマーカーです.
さらに関連する動画
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.5K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.6K
関連する概念動画
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Clinical Trials
7.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
7.8K
